Costar

Aeries Technology, Inc. Announces Two Executive Appointments

Retrieved on: 
Monday, November 13, 2023
Consulting, Asset Management, Professional Services, Finance, Sale, Freescale Semiconductor, MakeMyTrip, UST (company), Carvana, Lightower Fiber Networks, Record, Acquisition, Sidera Networks, Bachelor of Technology, Zulily, Paytm, Head, Investment, HarbourVest Partners, History, FP, Columbia Business School, Bank, Crediton, Brigham Young University, GE Capital, Pinterest, Delivery Hero, Master of Accountancy, IIT Kharagpur, Thrillist, Credit, IPO, MBA, Integral Ad Science, Internet, Growth, Family, Momentive (software company), AI, Microsoft, Bank of America, Innovation system, Corporate finance, Arista Networks, Initial public offering, Trivago, Management, Plarium, Citigroup, Costar, Aerie Pharmaceuticals, Purple, Grubhub, Dosh, Walmart, Intuit, Fiverr

“I am thrilled to welcome both Rajeev and Daniel to the Aeries family,” said Sudhir Panikassery, Chief Executive Officer and Co-Founder of Aeries.

Key Points: 
  • “I am thrilled to welcome both Rajeev and Daniel to the Aeries family,” said Sudhir Panikassery, Chief Executive Officer and Co-Founder of Aeries.
  • Previously, he served as the Chief Financial Officer of McLaren Technology Acquisition Corp. from 2021 to 2023, helping to lead their IPO and raising $205 million.
  • Mr. Nair earned his MBA from Columbia Business school and his Bachelor of Technology from IIT Kharagpur.
  • As an investment banker and private equity investor, he worked on transactions totaling approximately $40 billion in transaction value for disruptive technology companies.

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023
CD4, Survival, RNA, Costar, TIL, SITC, Annual general meeting, Cancer, Patient, Vaccine

New single-cell RNA sequencing data presented at the SITC 2023 Annual Meeting revealed enhanced gene signatures of activation and cytotoxicity in CoStAR-transduced CD4+ T cells, with significant increases in cytotoxic function of these CD4+ T cells in an in vitro cytotoxicity assay.

Key Points: 
  • New single-cell RNA sequencing data presented at the SITC 2023 Annual Meeting revealed enhanced gene signatures of activation and cytotoxicity in CoStAR-transduced CD4+ T cells, with significant increases in cytotoxic function of these CD4+ T cells in an in vitro cytotoxicity assay.
  • “The data presented at the SITC 2023 Annual Meeting reinforce the potential of CoStAR to broadly enhance the function of TIL therapies through multiple functional enhancements,” said Bronson Crouch, CEO of Instil.
  • Posters may be found on the Instil Bio Publications webpage:
    POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5 2023
    Single cell RNA sequencing reveals functionally validated signatures of cytotoxicity in anti-FRα CoStimulatory Antigen Receptor (CoStAR™) activated CD4+ T cells.
  • POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5 2023
    Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) drives distinct cytokine-mediated proliferation responses in CD4+ and CD8+ T cells.

JLL names Patrick Saade Head of Global Hotels Desk

Retrieved on: 
Wednesday, October 4, 2023
Hospitality, RCA, Head, JLL, Sale, FX, Denihan Hospitality Group, Global Hotel Alliance, REA, Costar, Commercial property

LONDON, Oct. 4, 2023 /PRNewswire/ -- JLL today announced the appointment of Patrick Saade as Head of the JLL Hotels & Hospitality group Global Hotels Desk. Patrick joins the global Hotels & Hospitality leadership team that includes William Duffey in EMEA, Nihat Ercan in Asia Pacific and Kevin Davis in the Americas.

Key Points: 
  • LONDON, Oct. 4, 2023 /PRNewswire/ -- JLL today announced the appointment of Patrick Saade as Head of the JLL Hotels & Hospitality group Global Hotels Desk.
  • The Global Hotels Desk specialises in coordinating international capital by connecting interested investors with Hotels & Hospitality assets and portfolios for sale.
  • The appointment of Patrick Saade to lead our Global Hotels Desk reflects his exceptional contribution and contacts, demonstrating our ongoing commitment to connecting clients with capital."
  • Patrick Saade, Head of the Global Hotels Desk, commented, "Throughout my 13 years with JLL's Hotels and Hospitality Group, I am proud to have witnessed first-hand our team's unwavering commitment to be the leading advisor in hotels and hospitality real estate.

IDIS Co., Ltd. Announces the Closing of its Acquisition of Costar Technologies, Inc.

Retrieved on: 
Friday, August 18, 2023
OTC Markets Group, IDIS, McMillan, Tripura Merger Agreement, McMillan LLP, Acquisition, DLA Piper, Security (finance), Financial adviser, Costar

COPPELL, Texas, Aug. 18, 2023 /PRNewswire/ -- IDIS Co., Ltd. ("IDIS") (143160:KOSDAQ) and Costar Technologies, Inc. ("Costar") (OTC Markets Group: CSTI) are pleased to announce that pursuant to the terms of the previously announced merger agreement signed March 23, 2023 (the "Merger Agreement") IDIS has acquired all of the common stock of Costar (the "Costar Shares").

Key Points: 
  • COPPELL, Texas, Aug. 18, 2023 /PRNewswire/ -- IDIS Co., Ltd. ("IDIS") (143160:KOSDAQ) and Costar Technologies, Inc. ("Costar") (OTC Markets Group: CSTI) are pleased to announce that pursuant to the terms of the previously announced merger agreement signed March 23, 2023 (the "Merger Agreement") IDIS has acquired all of the common stock of Costar (the "Costar Shares").
  • Following the acquisition, Costar will continue to operate as a wholly-owned subsidiary of IDIS.
  • After customary working capital adjustments and payment of indebtedness and transaction expenses, Costar stockholders will receive approximately $4.90 in cash for each Costar Share and the Costar Shares will be delisted from the OTC Markets Group.
  • With the acquisition of Costar, IDIS, the largest video surveillance manufacturer in South Korea, expands its global presence and further diversifies its product portfolio.

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Retrieved on: 
Monday, June 26, 2023
Society, MBBS, Gene, TIL, Cancer, Ovary, NSCLC, Lung cancer, Doctor of Philosophy, Trial of the century, TCR, TILS, Costar, Patient, Melanoma, Carcinoma, Cell, Conference, Medical imaging, DALLAS

DALLAS, June 26, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported an oral presentation at the British Society for Gene and Cell Therapy Annual Conference, demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR) platform enhances activity of TILs against autologous tumor.

Key Points: 
  • The presentation highlighted CoStAR’s unique mechanism of action which results in greatly enhanced activity of TILs when activation occurs through both the native TCR and engineered CoStAR receptors.
  • Additionally, novel data demonstrated that Instil’s FRα-CoStAR enhances activity of TILs against autologous tumors with varied expression of FRα including ovarian, renal, and non-small cell lung cancer tumors.
  • The robust activity of NSCLC, ovarian, and renal carcinoma CoStAR-TILs against autologous tumor exceeded that of genetically unmodified melanoma TILs, as measured by secretion of IFNγ.
  • “These preclinical data continue to support our excitement around the anticipated resumption of the clinical study of ITIL-306 in patients with advanced cancers which express FRα.”

Gray Capital Releases First CRE Loan Maturity Report

Retrieved on: 
Tuesday, June 6, 2023
Federal Reserve Bank, Federal Reserve Bank of St. Louis, Communication, Research, Commercial property, Acquisition, Mortgage Bankers Association, Investment, Bloomberg L.P. v. Board of Governors of the Federal Reserve System, Capital, History of Federal Open Market Committee actions, Commercial, CRE, Federal Open Market Committee, Environment, FOMC, Distress, Real estate, Costar

INDIANAPOLIS, June 6, 2023 /PRNewswire/ -- Gray Capital, a family-owned and operated private equity real estate firm specializing in the strategic investment and acquisition of multifamily apartments in growing markets throughout the Midwest, today announces the release of its first report on Loan Maturities and Distress in the Multifamily Investment Market. These reports will be updated and published quarterly with new insights and analysis by Gray Capital.

Key Points: 
  • These reports will be updated and published quarterly with new insights and analysis by Gray Capital.
  • Gray Capital report predicts a wave of anticipated commercial real estate debt maturities in October 2023.
  • "Gray Capital is the right team, right firm, and in the right markets to have an edge in today's challenging environment," said Spencer Gray, CEO of Gray Capital.
  • To learn more about Gray Capital, visit www.graycapitalllc.com or follow Gray Capital on Instagram .

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC – CS

Retrieved on: 
Thursday, March 30, 2023
Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., IDIS, Tripura Merger Agreement, Brodsky, KNX, Knight-Swift, U.S. Express, Diffusion, NYSE, Costar, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the deal, Diffusion will merge with EIP Pharma Inc. (“EIP Pharma”).
  • Under the terms of the agreement, U.S. Express will be acquired by Knight-Swift Transportation Holdings Inc. (NYSE - KNX) (“Knight-Swift”).
  • U.S. Xpress stockholders will receive $6.15 per share in an all-cash transaction, representing an enterprise value of approximately $808 million.

IDIS Co., Ltd. to Acquire Costar Technologies, Inc.

Retrieved on: 
Friday, March 24, 2023
LLP, Imperial Capital, IDIS, Tripura Merger Agreement, McMillan, OTC Markets Group, Mergers and acquisitions, McMillan LLP, Acquisition, Engineering, Piper, DLA Piper, Security (finance), Costar

The Merger Agreement has been unanimously approved by the boards of directors of each of IDIS and Costar.

Key Points: 
  • The Merger Agreement has been unanimously approved by the boards of directors of each of IDIS and Costar.
  • The board of directors of Costar has recommended that Costar stockholders approve the transaction and adopt the Merger Agreement at a special meeting of the stockholders of Costar to be called in connection with the merger transaction.
  • IDIS will continue using the Costar name, with Costar becoming a wholly owned subsidiary of IDIS.
  • The present Costar management team and employees are expected to join IDIS following the closing of the acquisition.

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Retrieved on: 
Monday, January 9, 2023
RCC, TIL, Instil, Large-cell lung carcinoma, Costar, Safety, Ovary, Patient, Renal cell carcinoma, Ovarian cancer, Cancer, Pharmaceutical industry, NSCLC, DALLAS

DALLAS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next-generation tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the resumption of its Phase 1 clinical trial of ITIL-306 for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).

Key Points: 
  • With the resumption of the ITIL-306 Phase 1 study, the Company expects to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023.
  • The trial was resumed after the implementation of additional quality safeguards designed to further protect the manufacturing process from potential contaminants.
  • Following its recent reprioritization of clinical programs and corporate restructuring, Instil expects its cash runway to extend into 2025, excluding the potential financing or other monetization of its Tarzana manufacturing site.
  • Instil intends to provide further updates on its pre-clinical pipeline in 2023, including the potential to nominate additional CoStAR candidates and novel TIL technologies for clinical development.

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Retrieved on: 
Thursday, December 8, 2022
Ovary, TIL, Head, Renal cell carcinoma, Tumor microenvironment, Failure, Ovarian cancer, TME, Safety, Cancer, TILS, Large-cell lung carcinoma, Workforce, Research, Cervical cancer, Costar, COVID-19, Patient, Lead, Pharmaceutical industry, Medical imaging, Instil, DALLAS, NSCLC

The Company expects to report data from the dose escalation cohorts of the Phase 1 ITIL-306 study in 2023.

Key Points: 
  • The Company expects to report data from the dose escalation cohorts of the Phase 1 ITIL-306 study in 2023.
  • Instil is undertaking a reduction in its U.S. workforce of approximately 60% to re-align its operating model from a registration-focused company to a development-stage company.
  • Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing next-generation TIL therapies for the treatment of patients with cancer.
  • Instil is advancing its lead CoStAR-TIL product candidate, ITIL-306, a next-generation, genetically-engineered TIL therapy for multiple solid tumors.